b1 integrin regulates the response of both normal and cancer cells to their local environment. Although mis-localised in prostate cancer, the role b1 integrin plays in prostate development and carcinogenesis remains unknown. To assess the role of b1 integrin in vivo, we conditionally deleted b1 integrin from prostate epithelium and subsequently crossed these mice to the TRAMP prostate carcinogenesis model. Deletion of b1 integrin following castration and subsequent androgen supplementation resulted in an expansion of the p63-positive basal cell population and decreased differentiation. Consistent with these findings, deletion of b1 integrin in TRAMP mice decreased animal survival, decreased retention of normal prostate morphology, increased the percentage of tissue with poorly differentiated carcinoma, and increased cell proliferation. This study demonstrates that b1 integrin regulates several aspects of normal prostate development and in contrast to its role in several other tissues, its loss is associated with increased rates of prostate tumour progression. P rostate cancer is responsible for the second highest number of cancer-related deaths, after lung cancer and statistically 1 in 33 men will die from the disease 1 . Prostate cancer is thought to arise in the secretory glandular cells of the prostate, predominately producing adenocarcinomas. Associated initially with the precursor lesion prostatic intra-epithelial neoplasia (PIN) the disease can progress through to castration-resistant metastatic disease, for which few therapeutic options exist. It is imperative therefore, to understand the gene and protein changes that contribute to the progression from normal prostate tissue, PIN, adenocarcinoma, and eventually, androgen-independence and metastases.
b1 integrin regulates the response of both normal and cancer cells to their local environment. Although mis-localised in prostate cancer, the role b1 integrin plays in prostate development and carcinogenesis remains unknown. To assess the role of b1 integrin in vivo, we conditionally deleted b1 integrin from prostate epithelium and subsequently crossed these mice to the TRAMP prostate carcinogenesis model. Deletion of b1 integrin following castration and subsequent androgen supplementation resulted in an expansion of the p63-positive basal cell population and decreased differentiation. Consistent with these findings, deletion of b1 integrin in TRAMP mice decreased animal survival, decreased retention of normal prostate morphology, increased the percentage of tissue with poorly differentiated carcinoma, and increased cell proliferation. This study demonstrates that b1 integrin regulates several aspects of normal prostate development and in contrast to its role in several other tissues, its loss is associated with increased rates of prostate tumour progression. P rostate cancer is responsible for the second highest number of cancer-related deaths, after lung cancer and statistically 1 in 33 men will die from the disease 1 . Prostate cancer is thought to arise in the secretory glandular cells of the prostate, predominately producing adenocarcinomas. Associated initially with the precursor lesion prostatic intra-epithelial neoplasia (PIN) the disease can progress through to castration-resistant metastatic disease, for which few therapeutic options exist. It is imperative therefore, to understand the gene and protein changes that contribute to the progression from normal prostate tissue, PIN, adenocarcinoma, and eventually, androgen-independence and metastases.
A cell's survival and proliferative ability is usually governed by its environment, mediated by extracellular matrix receptors, which provide positional context and homeostatic signals. Integrins connect a cell to its local environment, and although lacking intrinsic kinase activity, mediate signals through the recruitment of a multitude of additional proteins 2 . Aberrant integrin-growth factor signalling has been identified in most cancers, and is thought to modulate tumour initiation and progression, and ultimately, metastasis 3 . Integrins regulate cell polarity, adhesion, survival, and proliferation, all processes which when dys-regulated, influence tumour phenotype. Deletion of b1 integrin in mouse models of breast and pancreatic cancer impair tumourigenesis and metastasis [4] [5] [6] . While use of function-blocking b1 integrin antibodies in 3D cultures of breast cancer cell lines has been shown to revert cancer phenotype, resulting in cancer cells with a more normal morphology and decreased proliferation [7] [8] [9] , making integrins valid targets for therapeutics. At a cellular level the prostate is comprised of a hormone-responsive polarised secretory luminal epithelium, surrounded by a myo-epithelial layer, in contact with a laminin-rich basement membrane. b1 integrin is widely expressed and known to control many developmental processes 2 , and in the adult prostate it is expressed predominantly on the baso-lateral surfaces of the epithelial cells 10 . Studies utilising either primary, or immortalised, prostate epithelial cells have demonstrated a role for b1 integrin in regulating differentiation in prostate cells. Function-blocking antibodies to b1 integrin in 3D cultures of RWPE-1 cells significantly reduces acinar formation 11 . Similarly, b1 integrin was demonstrated to negatively regulate prostate epithelial cell differentiation in primary human cell cultures 12 , indicating a potential, but untested, role for b1 integrin in prostate development and function in vivo.
b1 integrin expression is both up-regulated and mis-localised during progression of prostate cancer 10, 13 , demonstrating the potential clinical importance of the undefined role of b1 integrin in prostate cancer. Although a number of studies have investigated the roles of b1 integrin using prostate cancer cell lines [14] [15] [16] [17] [18] [19] role of b1 integrin in signalling between the melee of extracellular matrix proteins and the prostate cell remains undefined, making it imperative to examine this protein in the context of the normal (or in cancer, aberrant) cellular environment and extracellular matrix.
To redress this absence of in vivo data, we have used transgenic mouse models. The TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) model 14 is one of the best characterised animal models of prostate tumourigenesis, effecting a reproducible and hormoneresponsive model of prostate cancer which closely mimics the human disease. In this model the activity of the p53 and Rb tumour suppressor genes is abrogated in prostate epithelial cells by driving expression of the simian virus 40 early T/t antigen genes, from the prostate-specific probasin promoter. TRAMP mice develop PIN and proliferative lesions that progress from well-differentiated carcinoma (WDC) to poorly-differentiated carcinoma (PDC) and eventually undergo metastasis to the lungs and lymph nodes [14] [15] [16] . Using ARR2PBi-Cre 17 transgenic mice, which drive high level Cre expression under the control of a composite androgen-responsive probasin promoter to all lobes of the prostate and LoxP-flanked b1 integrin (Itgb1 fl/fl ) mice 18 , we have specifically ablated b1 integrin in the prostate epithelium, enabling us to examine the effect of loss of this receptor during both normal tissue maintenance, and in the context of TRAMP-mediated prostate tumour formation and progression. Given the evidence presented above, we hypothesised that b1 integrin signalling is required for normal prostate development, and furthermore, that by ablating its expression, prostate tumour progression can be delayed or moderated.
Results
Deletion of b1 integrin in prostate epithelium. Prostate epithelial specific b1 integrin null mice were generated by crossing Itgb1 fl/fl18 mice to ARR2PBi-Cre (Cre) 17 transgenic mice. The specificity of Cremediated recombination was determined using PCR analysis, and showed that DNA from wild-type mice Itgb1 ;Cre animals reveal specific ablation of b1 integrin expression in the luminal epithelial cells, but b1 integrin retention within the stromal tissue in Creexpressing animals (Figures 1c and d) . This is consistent with the presence of Cre staining within the epithelial cells, but not the stroma (Figures 1e and f) .
b1 integrin regulates the basal epithelial cell population during castration/ testosterone-driven development. Expression of ARR2PBi-Cre is strongest post-puberty, as a result of the androgenresponse elements within the promoter. To investigate the role that b1 integrin plays in normal prostate tissue maintenance, we examined ventral, lateral, and dorsal prostate lobes at 9, 26 ( Figure 2a ), and 60 weeks of age, using H&E staining. These analyses reveal no gross morphological differences between the two genotypes, indicating no essential requirement for b1 integrin in post-pubertal prostate development, nor in prostate tissue maintenance.
We next used castration and subsequent testosterone supplementation ( Figure 2b The basic helix-loop-helix transcription factor, Mist1, has been proposed to regulate serous exocrine cell differentiation 23 . IHC using an antibody against Mist1 showed that the majority of luminal epithelial cells in Itgb1 Expression of b1 integrin during prostate carcinogenesis in TRAMP mice parallels b1 integrin expression in human prostate cancer. b1 integrin has been identified in a number of studies as being both mislocalised and up-regulated in expression during prostate cancer progression 10, 13 . To investigate the role that this protein plays in prostate cancer and the validity of utilising the TRAMP model with respect to b1 integrin function during prostate carcinogenesis, we examined b1 integrin protein levels during prostate cancer progression in TRAMP mice. Prostates were dissected out, and one half paraffin-embedded, the other half lysed for protein. Using H&E analyses to grade the prostate tumour morphology, protein was extracted from the corresponding half and subjected to western analysis. Consistent with the previous observations of Goel and colleagues 24 , b1 integrin was expressed in normal mouse prostate (Figure 1b) , with protein levels increasing during the progression from prostatic intraepithelial neoplasia into well-differentiated carcinoma. However, as the tumour progresses, and becomes poorly differentiated (poorly-differentiated carcinoma), b1 integrin expression is lost ( 24 and see Supplementary Fig. 2 Loss of b1 integrin results in earlier, more aggressive tumours. To further characterise the effect of deleting b1 integrin in TRAMPmediated prostate carcinogenesis, we performed a cross-sectional analysis. Prostate lobes were collected, paraffin-embedded, and histological examination performed using H&E staining. Tissue was graded according to Gingrich et al., 15 . We first scored the percentage of mice within the cohort presenting with a particular pathology (ie normal, PIN, WDC, PDC) regardless of the percentage of the gland occupied by the pathology/lesion. At 15 weeks, the ventral prostates of all of the TRAMP tg/1 ;Itgb1 fl/fl ;WT mice retained at least some normal-appearing prostate epithelium, whereas only 50% of TRAMP tg/1 ;Itgb1 fl/fl ;Cre mice retained regions of normal prostate tissue (Figure 3b(i) ). Within the same cohort of animals, 37.5% of the TRAMP tg/1 ;Itgb1 fl/fl ;Cre mice had progressed to PDC, (Figure 3b ;Itgb1 fl/fl ;WT mice. These data indicate that the decreased average survival time observed in b1 integrin null mice is, presumably due to the increased proportion of tissue with higher grade lesion.
Deletion of b1 integrin increases prostate epithelial cell proliferation. b1 integrin deletion has been shown to suppress cell proliferation in two mouse mammary tumourigenesis models 4, 6 subsequently resulting in impaired tumourigenesis. Decreased survival times and an enhancement in progression of pathological grade following loss of b1 integrin in the prostate prompted an examination of the proliferative status of these tumours. Quantification of Ki67 expression levels by IHC (representative images of Ki67 staining are shown in Figure 3f) (Figure 3d) , consistent with the increased tumour progression observed in our cross-sectional and survival analysis.
Discussion
We have detailed herein the first conditional deletion of b1 integrin from mouse prostate epithelium, allowing us to investigate the role of this extra-cellular matrix receptor in the context of the signalling and extra-cellular environment of the prostate during development, in tissue maintenance, and utilised the TRAMP model to gain insight into its role in prostate cancer.
b1 integrin has been shown to play an essential role in the regulation of cell phenotype and function in a number of different systems (reviewed in 25 ) including mammary gland, where conditional deletion has demonstrated a critical role for b1 integrin in maintaining the structural integrity of alveoli and regulating epithelial cell proliferation and differentiation during glandular development 26, 27 . In contrast to these tissues, histological analyses of animals lacking expression of b1 integrin in prostate epithelium reveal no requirement for the receptor in normal tissue maintenance, possibly indicating functional compensation from other b integrins expressed in prostate epithelium (reviewed by Goel and colleagues 28 ), or that b1 integrin is functionally redundant once an appropriate basal lamina has formed in development.
To further test the requirement of b1 integrin in the prostate, we used castration and subsequent androgen supplementation, to force prostate regeneration and remodeling in the absence of b1 integrin. The defect in differentiation observed is consistent with studies implicating b1 integrin as required for terminal differentiation. The role of b1 integrin in keratinocyte differentiation has been extensively studied, revealing that reduction of b1 integrin is required to both reduce adhesion to the basement membrane, and in turn, initiate differentiation 29 . This has been further dissected to show that adhesion to extra-cellular matrix proteins suppresses terminal differentiation 30, 31 . Studies performed by Bagutti and colleagues 32 indicate that b1 integrin is required to enhance sensitivity of keratinocytes to factors secreted by dermal fibroblasts, such as Keratinocyte Growth Factor (KGF or FGF7), indirectly demonstrating an interaction between b1 integrin and the KGF receptor (FGFR2IIIb). KGF and b1 integrin have also been shown to act in concert to regulate differentiation of primary human prostate epithelial cells in culture 12 . KGF is a paracrine regulator of ductal growth and branching morphogenesis of the developing prostate 33 , and treatment of primary human prostate epithelial cells with KGF induces both a decrease in a2b1 integrin expression, as well as an increase in the proportion of cells expressing prostate epithelial differentiation markers. This differentiation effect is restricted to the CD133 2 population, thought to represent the transit amplifying cells, thus enabling the prostate to continue to produce both a differentiated epithelial compartment, as well as maintain the (CD133 1 ) stem cell population. The increase in p63-positive basal epithelial cells observed in our Itgb1 fl/fl ;Cre animals after castration and testosterone supplementation may be indicative of a temporary increase in proliferation (although no differences in Ki67 were observed (data not shown), similar to that observed with b1 integrin blockade by Heer and colleagues 12 ) which, with sufficient exposure to paracrine factors such KGF, results in delayed, but not inhibited, differentiation, as evidenced by the decrease in Mist1 staining.
Utilising the TRAMP model of prostate carcinogenesis, increased percentages of higher tumour grades were observed in b1 integrindeleted animals (Figure 3b ), as were higher proliferative rates (Figure 3c ). These alterations are of pathological relevance, resulting in a small decrease in median survival time, as indicated by KaplanMeier survival analysis (Figure 3a) . Using a second mouse model of prostate cancer (in which PTEN is deleted from prostate epithelium 34 ) to further investigate the role of b1 integrin, suggests that similar to the TRAMP model, deletion of b1 enhances progression of tumourigenesis (preliminary results; data not shown). This is in contrast to several studies performed using b1 integrin deletion in mouse tumourigenesis models, such as breast, in which loss of b1 results in a decrease in proliferation, a block of tumour induction 6 , or a decrease in metastatic potential 4 . However, it should be noted, that unlike in prostate cancer, where b1 integrin levels initially increase with loss of differentiation 10, 13 , b1 integrin levels decrease in breast cancer 35 , and that b1 integrin levels do not correlate with patient survival in breast cancer mRNA expression arrays 36 . b1 integrin also regulates normal mammary epithelial cell proliferation and morphology during mammopoiesis 26 , whereas we have demonstrated here that ablation of b1 integrin in the prostate has no effect on proliferation, or gland morphology, and a mild effect on differentiation following castration/androgen supplementation.
A number of factors complicate the study of individual integrins both in vitro and in vivo. Firstly, integrins are obligate heterodimers, requiring an alpha and a beta sub-unit. The functional redundancy of specific a/b heterodimers has been well characterised. In the mouse mammary gland, deletion of either a3 or a6, both partners of b1 integrin, has no effect on mammary gland development 37 , whereas deletion of b1 integrin, which results in ablation of both a3b1 and www.nature.com/scientificreports SCIENTIFIC REPORTS | 2 : 526 | DOI: 10.1038/srep00526a6b1, has a significant mammary phenotype 27 . In addition, while complete deletion of b1 integrin inhibits tumour growth and metastasis, targeting of the a2b1 heterodimer has the opposite effects in breast cancer cells 36 , indicating both context and heterodimer specific roles for individual integrins. In prostate cancer, the likely b1 integrin heterodimers present are a2b1 and a6b1, given the aberrant expression of both a2 and a6 sub-units (reviewed in 28 ), deletion of the b1 sub-unit is likely to have knock-on effects. The increase in tumour progression and cell proliferation observed in this study following b1 integrin deletion in the prostate, is consistent with a2b1 integrin being the dominant integrin heterodimer in the prostate.
Finally, b1 integrin also has a number of different isoforms, of which b1a and b1c have been reported in human prostate [38] [39] [40] . The b1c isoforms however, are not present in the mouse genome 41, 42 . Differing in the cytoplasmic tail, and therefore altering binding partners, experiments performed in prostate cell lines indicate opposing roles for these isoforms, inducing and inhibiting cellular proliferation, and decreasing and enhancing adhesion to the basement membrane, respectively 24, [43] [44] [45] [46] . While the roles played by individual isoforms of b1 integrin have yet to be elucidated, our results indicate that b1 integrin acts to modulate proliferation in prostate cancer, with its loss resulting in enhanced tumour progression in the TRAMP mouse model. From work performed on human prostate cancer cell lines, Goel and colleagues 44 have hypothesised that reexpression of the b1c integrin isoforms may be sufficient to revert a neoplastic phenotype to a non-proliferative and highly adherent phenotype. Our results presented here are consistent with the idea that human prostate tumour progression is driven not by increasing expression of b1a integrin, but rather, by the loss of b1c integrin.
We conclude that although previous studies have indicated a requirement for b1 integrin in tumour cell proliferation and differentiation, our studies in mouse prostate epithelium indicate that b1 integrin regulates epithelial cell specification and differentiation in normal prostate, and that deletion of b1 integrin in prostate cancer can result in enhanced tumourigenesis and proliferation. Therefore, therapeutic strategies aimed at inhibiting this receptor in prostate cancer may prove not to be beneficial, and that downstream pathways, such as those mediated by Integrin-linked kinase or Focal adhesion kinase, should be investigated.
Methods
Mouse strains and breeding. The animal experimentation described within this study was approved by the Garvan Institute and St Vincent's Hospital Animal Ethics Committee.
The Itgb1 fl/fl , TRAMP tg/1 , and ARR2PBi-Cre mice have been described previously 14, 17, 18 . Animals were crossed as described in the relevant sections, and where possible, the Cre and TRAMP transgenes were carried by the female parent to avoid any potential issues with fertility.
Genotyping was performed for Itgb1 , and ARR2PBi-Cre, as outlined by the Jackson Laboratory. Recombination of the Itgb1 fl/fl locus was confirmed as previously described 47 using primers: b1-5 Forward 59-CGCAGAACAATAGGTGCTGAAATTAC-39 and b1-3 Reverse 59-CCACAACTTTCCCAGTTAGCTCTC-39 which are located either side of the loxP insertion sites. A 300 bp amplicon is produced when recombination has occurred.
Morphological, histological, and immuno-histochemical analyses. Lateral, ventral, dorsal, and anterior (coagulating gland) prostate lobes were removed from mice, and one of each lobe fixed in 10% buffered formalin for 4 hours, transferred to 70% ethanol overnight, before being embedded in paraffin (the remaining lobes were flash frozen with liquid nitrogen). Morphological analyses were performed by examination of 4 mm sections stained with haematoxylin and eosin (H&E). For immunohistochemical analysis, endogenous peroxidase activity was blocked using 3% hydrogen peroxide. Antibodies and the retrieval methods used were: b1 integrin, 1/20000 dilution (Millipore, Clone MB1.2) Dako s2367, pressure cooker retrieval; Mist1, (C. Pin, University of Western Ontario, Canada) 0.05% citraconic anhydride, pressure cooker retrieval; p63, 1/100 dilution (Dako Clone 4A4) 0.05% citraconic anhydride, pressure cooker retrieval; and Ki67, 1/100 dilution (Lab Vision Neomarkers, Clone SP6), Dako s1699, pressure cooker retrieval. Primary antibodies were detected using HRP-conjugated secondary antibody, and DAB detection. Sections were counter-stained with haemotoxylin.
Quantification of Ki67 and p63 was performed by taking either .6 random low magnification images, or images of .10 acini, respectively, and using ImageJ to count the stained and unstained epithelial cells. ;Cre) were castrated at 15 weeks of age. Three weeks postsurgery, testosterone pellets (5 mg, 21 day release; Innovative Research of America) were implanted subcutaneously in the upper back of mice. Animals were sacrificed 2 weeks post-supplementation for analysis. A small number of castrated animals were sacrificed at 18 weeks to assess the extent of involution.
Survival and statistical analysis. For survival analyses, animals were sacrificed once tumour burden was either determined to reach 10% initial body weight, or cause distress to the animals (as dictated by the Garvan Animal Ethics guidelines, including hunched posture, poor coat condition, difficulty breathing, and failure to respond to stimuli), requiring euthanasia. For cross-sectional analyses, lateral, ventral, dorsal, and anterior prostate lobes were collected at 9, 12, 15, 18, and 24 weeks of age, with at least 8 animals of each genotype for each time point. Liver, lung, kidney, and periaortic lymph nodes were examined visually at necropsy for metastases.
Data, where indicated, are represented as mean6SEM, and statistical analysis performed using Student's t-test and GraphPad Prism software. Kaplan-Meier survival analysis and the Mantel-Cox log-rank test were performed using GraphPad Prism software.
